EarningsQ2 2026 Earnings Report
MX:QIAN Q2 2026 EPS Results
Actual EPS$11.39
Consensus EPS$10.99
Beat/MissBeat by +$0.40
One Year Ago EPS$11.61
MX:QIAN Q2 2026 Revenue Results
Actual Revenue$9.83B
Expected Revenue$9.69B
Beat/MissBeat by +$138.51M
YoY Revenue Growth+0.28%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
MX:QIAN Upcoming Earnings
Qiagen's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:QIAN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was broadly positive: management reported results above outlook for sales and adjusted EPS, strong cash generation, high profitability, and clear momentum in key growth pillars (Sample Technologies, QIAcuity, QDI) alongside active product launches and capital returns (40% dividend increase, $500M repurchase). Challenges include declines in QIAstat and PCR product groups, China and regional softness, a notable revenue loss from reduced immigration testing (~$35M) affecting QuantiFERON comparisons, modest margin and inventory pressures, and ongoing strategic/leadership transition that creates near-term uncertainty. On balance, the company emphasized confidence in a stronger second half of 2026 driven by new product rollouts and easing comparables.Company Guidance
Beat on Sales and EPS
Net sales of $535 million, unchanged year-over-year and at CER, ahead of outlook for ~2% decline at CER; adjusted diluted EPS of $0.62 (reported and at CER) above outlook of at least $0.60 at CER.
Growth Pillars Outperform
Growth pillars delivered 5% growth at CER, outpacing market growth; Sample Technologies led with +9% CER growth, QIAcuity delivered double-digit growth at CER, and Qiagen Digital Insights (QDI) achieved solid single-digit growth.
QuantiFERON Recovery
QuantiFERON returned to growth (+1% CER) as broader testing demand offset prior declines in U.S. immigration testing; management is tracking toward a $500 million target for QuantiFERON in 2026.
Strong Profitability and Margin Recovery
Adjusted operating income of $157 million (adjusted operating margin 29.4% vs. 29.9% year-ago) and sequential margin improvement of ~200 basis points from Q1 2026 (27.4% to 29.4%), reflecting efficiency gains and disciplined cost management.
Robust Cash Generation and Balance Sheet Actions
Operating cash flow of $301 million for the first six months (unchanged YoY) despite ~$20 million of efficiency/restructuring payments and inventory build; completed $500 million synthetic share repurchase in January and paid second annual dividend (~$72 million).
Dividend Increase
Dividend per share raised by 40% to $0.35 from $0.25, signaling confidence in cash flow and capital return capacity.
Reaffirmed Full-Year Outlook and H2 Acceleration
Reaffirmed full-year guidance: total net sales growth of ~1–2 percentage points at CER and adjusted diluted EPS of at least $2.43 at CER; expect H2 CER growth improvement from -1% (H1) to ~3–4% (H2) driven by end of discontinued-product headwinds, new product launches and Parse contribution.
Product and R&D Momentum
Multiple new product launches and pipeline progress: commercial launch of QIAsymphony Connect and placements of QIAsprint Connect; QIAmini on track for fall launch; Parse single-cell advances and NASA-selected research collaboration; QIAstat menu expansion with new BCID panels and expected FDA submission by year-end.
MX:QIAN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed